Standout Papers
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (2016)
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater (2019)
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021)
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019)
- Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 (2024)
Immediate Impact
3 by Nobel laureates 7 from Science/Nature 85 standout
Citing Papers
Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 Standout
Works of Rina Hui being referenced
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Rina Hui | 11054 | 7176 | 1871 | 2387 | 169 | 13.8k | |
| Scott Gettinger | 9980 | 6665 | 1688 | 2654 | 255 | 12.8k | |
| Edward B. Garon | 10814 | 7641 | 2051 | 2513 | 326 | 14.3k | |
| Gilberto de Castro | 7823 | 5286 | 1747 | 1316 | 212 | 10.4k | |
| Laura Q.M. Chow | 8861 | 4544 | 1594 | 2951 | 156 | 12.1k | |
| Carlos H. Barrios | 10539 | 6945 | 4268 | 1970 | 265 | 15.5k | |
| Geoffrey R. Weiss | 7763 | 4353 | 1438 | 2435 | 191 | 12.3k | |
| Maya Gottfried | 10411 | 7572 | 1690 | 1924 | 155 | 12.9k | |
| Katsuyuki Hotta | 10920 | 8489 | 1691 | 1916 | 286 | 13.7k | |
| William L. Dahut | 5115 | 4224 | 1583 | 2798 | 288 | 10.1k | |
| Igor Bondarenko | 12964 | 8783 | 3459 | 1823 | 303 | 17.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...